Rosenberg Ellen

Avg. Two Year Performance

115% Avg. Purchase Return
47% Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return(25%)(13%)(15%)10%115%
Purchase Success Rate0 of 10 of 10 of 11 of 11 of 1
Average Sale Return2%(3%)(15%)0%0%
Sale Success Rate2 of 61 of 60 of 60 of 60 of 6

Amicus Therapeutics, Inc.

Drugs » Biotechnology

Chief Legal Officer:

Holdings: 382.65K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--